Wells Fargo & Company Exelixis, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Exelixis, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 746,286 shares of EXEL stock, worth $26.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

746,286

Previous 42,943 1637.85%

Holding current value

$26.1 Million

Previous $1.11 Million 2130.79%

% of portfolio

0.01%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$25.39 - $36.46 $17.9 Million - $25.6 Million	703,343 Added 1637.85%	746,286 $24.9 Million
Q3 2024 Nov 13, 2024	SELL	$21.96 - $27.6 $555,170 - $697,755	-25,281 Reduced 37.06%	42,943 $1.11 Million
Q2 2024 Aug 13, 2024	SELL	$20.34 - $23.73 $532,623 - $621,393	-26,186 Reduced 27.74%	68,224 $1.53 Million
Q1 2024 May 10, 2024	BUY	$20.17 - $23.93 $771,684 - $915,537	38,259 Added 68.14%	94,410 $2.24 Million
Q4 2023 Feb 09, 2024	SELL	$19.25 - $24.13 $1.23 Million - $1.54 Million	-63,880 Reduced 53.22%	56,151 $1.35 Million
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $301,079 - $359,587	-15,813 Reduced 11.64%	120,031 $2.62 Million
Q2 2023 Aug 15, 2023	BUY	$18.17 - $20.48 $360,947 - $406,835	19,865 Added 17.13%	135,844 $2.6 Million
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $2.75 Million - $3.27 Million	-168,440 Reduced 59.22%	115,979 $2.25 Million
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $258,194 - $300,134	-17,259 Reduced 5.72%	284,419 $4.56 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $399,761 - $567,773	-25,495 Reduced 7.79%	301,678 $4.73 Million
Q2 2022 Aug 12, 2022	SELL	$17.44 - $23.16 $2.44 Million - $3.24 Million	-140,074 Reduced 29.98%	327,173 $6.81 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $730,655 - $972,633	42,904 Added 10.11%	467,247 $10.6 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $11.3 Million - $15.6 Million	-712,394 Reduced 62.67%	424,343 $7.76 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $10.3 Million - $13.4 Million	633,192 Added 125.75%	1,136,737 $24 Million
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $387,109 - $551,226	-21,566 Reduced 4.11%	503,545 $9.17 Million
Q1 2021 May 13, 2021	BUY	$20.53 - $25.22 $436,139 - $535,773	21,244 Added 4.22%	525,111 $11.9 Million
Q4 2020 Feb 09, 2021	SELL	$18.39 - $24.8 $909,422 - $1.23 Million	-49,452 Reduced 8.94%	503,867 $10.1 Million
Q3 2020 Nov 05, 2020	SELL	$20.67 - $26.94 $837,610 - $1.09 Million	-40,523 Reduced 6.82%	553,319 $13.5 Million
Q2 2020 Aug 13, 2020	SELL	$16.46 - $27.42 $216,662 - $360,929	-13,163 Reduced 2.17%	593,842 $14.1 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $8.78 Million - $13.2 Million	607,005 New	607,005 $10.5 Million

Others Institutions Holding EXEL

# of Institutions

569

Shares Held

249M

Call Options Held

1.72M

Put Options Held

1.54M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Exelixis, Inc. Transaction History